 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Medidata Solutions (MDSO) provides cloud-based clinical development solutions for life sciences organizations in the United States and internationally.
The companys solutions comprise software and services that allow customers to increase the value of their clinical development by designing, planning, and managing key aspects of the clinical trial process, including study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding, clinical business analytics, and data flow and interoperability. It offers Medidata Rave, a platform for capturing and managing clinical data; Medidata CTMS, a clinical trial management solution that streamlines operational workflows; Medidata Designer, a study and protocol design tool that enhances the efficiency of clinical trial start-up; Medidata Insights, a business analytics platform; and Medidata Balance, a randomization and trial supply management solution.
The company also provides Medidata Grants Manager, which enables to develop and manage trial budgets; Medidata contract research organization (CRO) Contractor, an analytical tool for CRO outsourcing, budgeting, and negotiation; and iMedidata, a hosted portal application that allows investigative sites and sponsor study teams to start trial activities. In addition, it offers hosting, support, and professional services.
The company serves pharmaceutical, biotechnology, medical device, and diagnostics companies, as well as institutions, clinical research organizations, and other entities engaged in clinical trials. Medidata Solutions, Inc. markets and sells its application services through a direct sales force, as well as through relationships with CROs and other strategic partners.
Shares have formed a bullish "Cup & Handle" and higher share prices are expected for this stock.
52-Week Trading Range: $18.84 - 63.89
Entry Point: $61.50
Stop Loss: $58.42
Target Price: $67.65
MDSO fell below our stop loss.
